Global Diabetic Macular Edema Treatment Industry to 2027 - Key Market Trends and Drivers - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 30, 2021--
The “Diabetic Macular Edema Treatment - Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.
Amid the COVID-19 crisis, the global market for Diabetic Macular Edema Treatment estimated at US$3.8 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 1.9% over the analysis period 2020-2027.
Anti-VEGF, one of the segments analyzed in the report, is projected to record a 2.1% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroid segment is readjusted to a revised 1.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 1.5% CAGR
The Diabetic Macular Edema Treatment market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$752 Million by the year 2027 trailing a CAGR of 1.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 1.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
Other Products Segment to Record 1.6% CAGR
In the global Other Products segment, USA, Canada, Japan, China and Europe will drive the 1.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$487.9 Million in the year 2020 will reach a projected size of US$546.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$482.8 Million by the year 2027.
Select Competitors (Total 38 Featured):
- Acucela Inc.
- Aerie Pharmaceuticals, Inc.
- Aerpio Pharmaceuticals
- Antisense Therapeutics Limited
- Araim Pharmaceuticals, Inc.
- BCN Peptides S.A.
- Biomar Microbial Technologies
- Charlesson LLC
- Coherus BioSciences
Key Topics Covered:
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/r/vuhe5k
View source version on businesswire.com:https://www.businesswire.com/news/home/20211230005215/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: DIABETES PHARMACEUTICAL OPTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 12/30/2021 10:41 AM/DISC: 12/30/2021 10:41 AM